MOTS-c

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino acid mitochondria-derived peptide (MDP) discovered and characterized by researchers at the University of Southern California in 2015. Unlike most peptides studied in the research-chemical space, MOTS-c is endogenously encoded within the mitochondrial genome — specifically within the 12S rRNA gene — making it a naturally occurring signaling molecule rather than a synthetic analog. It belongs to the emerging class of mitochondrial-derived peptides (MDPs), which also includes humanin and SHLP1-6, and is increasingly studied in the context of metabolic physiology and geroscience.

At the mechanistic level, research suggests MOTS-c acts as an exercise-responsive mitohormetic signal. Studies indicate it translocates to the nucleus under cellular stress conditions — particularly glucose restriction and exercise — where it appears to interact with the AMPK pathway, upregulate folate cycle activity, and modulate reactive oxygen species (ROS). Animal model data published in Cell Metabolism (Lee et al., 2015) demonstrated that exogenous MOTS-c administration improved insulin sensitivity, reduced obesity phenotypes in diet-induced obese mice, and activated AMPK in skeletal muscle. Separately, in vitro data suggest MOTS-c may suppress pro-inflammatory cytokine signaling, which has drawn interest in the context of age-related chronic inflammation.

The human evidence base for MOTS-c remains limited but directionally consistent. Observational data published in PNAS (2021) found significantly elevated plasma MOTS-c levels in Japanese centenarians compared to younger controls, lending credibility to its putative longevity association. A small human interventional pilot study conducted in older adults reported that exogenous MOTS-c administration was associated with improvements in insulin sensitivity and physical performance metrics, though this research remains preliminary and has not been replicated at scale. Animal studies in aged mice have shown improvements in physical endurance and metabolic markers, with one study reporting performance improvements in running tests. These effects are reported in animal and early-phase human research contexts and should not be extrapolated to guaranteed human outcomes. Anecdotal self-reports from the biohacking community describe improved exercise recovery, heightened energy levels, and subjective metabolic improvements, but these accounts carry no controlled-study validity.

Dosing ranges reported in published research contexts vary. Human pilot research has investigated doses in the range of 0.5–10 mg per administration, while animal studies have used weight-based dosing equivalent to approximately 5–15 mg/kg in murine models (not translatable directly to human dosing without pharmacokinetic bridging studies). Subcutaneous injection is the predominant route used in research settings. This information is reported from research contexts only and constitutes no recommendation for human use. Individual pharmacokinetics, safety at repeated human doses, and long-term effects have not been established through controlled human trials. Content on this page is for educational purposes only and is not medical advice.

Legal status: MOTS-c is not approved for human use by the FDA, MHRA, EMA, or TGA. It is currently sold exclusively as a research chemical in most jurisdictions and is not scheduled as a controlled substance in the US, UK, or EU as of the time of writing, though Australia's Therapeutic Goods Administration classifies unregistered peptides under increasingly restrictive scheduling frameworks. Sourcing quality varies significantly across vendors; researchers should prioritize suppliers providing HPLC-verified Certificates of Analysis from independent third-party laboratories, with mass spectrometry confirmation of molecular identity. Lyophilized powder form requires reconstitution with bacteriostatic water and should be stored frozen prior to reconstitution and refrigerated thereafter.